Table 1.
Study groups and the composition of different vaccines
| Vaccine component |
||||||||
|---|---|---|---|---|---|---|---|---|
| Group &Vaccine | pcDNA3.1/Mtb72F | Control DNA (empty vector) | CpG | TB10.4 | PLGA NP | BCG priming | ||
| With adjuvant and delivery system | A | NP-DNA-CpG-BCG | + | + | + | + | ||
| B | NP-DNA-TB10.4-BCG | + | + | + | + | |||
| No adjuvant no delivery system | C | DNA-BCG | + | + | ||||
| No delivery system | D | DNA-CpG-BCG | + | + | + | |||
| E | DNA-TB10.4-BCG | + | + | + | ||||
| No adjuvant | F | NP-DNA | + | + | ||||
| G | NP-DNA-BCG | + | + | + | ||||
| H | NP-control DNA | + | + | |||||
| I | NP-DNA-CpG | + | + | + | ||||
| control | J | Blank-NP | + | |||||
NPs: nanoparticles; DNA: pcDNA3.1/Mtb72F DNA vaccine; CpG: CpG oligodeoxynucleotides; TB10.4: TB10.4 recombinant protein; BCG: Bacillus Calmette–Guérin vaccine